A Phase 2 interventional study of ritonavir and saquinavir [Invirase] in HIV Infections, sponsored by Hoffmann-La Roche. Completed at 10 sites in 3 countries. Open to participants aged 4 Months to 6 Years. Per ClinicalTrials.gov, last updated 2016-03-07.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies testing ritonavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Ritonavir · HIV Infections.
Among the 124 studies testing ritonavir in HIV Infections, this one is the 98th largest by enrollment of the 119 interventional ones that give a count, is one of 10 that started in 2008, is one of 31 in phase 2, and was the 81st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →1 of the 124 studies testing ritonavir in HIV Infections is open now. Recruiting first, the newest first:
University College, London
Ages 4 wk–14 yrs
Ritonavir: first FDA approval 1996 (NORVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 4 Months to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 38 · Phase 3 25 · Phase 4 24
First in 1998; this study’s year is marked. 10 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 46 across the 119 interventional studies. Of the 112 that completed or were terminated, 33 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 124 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
67 studies in HIV Infections by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 65 finished, 8 (12%) have results posted.
Among the 67 studies in HIV Infections by Hoffmann-La Roche, this one is the 46th largest by enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2008, is one of 12 in phase 2, and was the 61st registered.
Hoffmann-La Roche’s HIV Infections studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 124 studies testing ritonavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 67 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the pharmacokinetics, safety and activity of saquinavir (Invirase hard gel capsules, film coated tablets or opened capsules) boosted by combination with ritonavir, in HIV-1 infected infants and children between the ages of 4 months and 6 years. Patients will commence treatment with saquinavir 50mg/kg bid plus ritonavir 2.5mg/kg or 3.0mg/kg (dependent on body weight), and a background antiretroviral regimen. If drug exposures are found to be dissimilar to those previously seen in older children and adults, or are associated with toxicities, subsequent dose adjustments will be made. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ritonavir · Drug: saquinavir [Invirase]
2.5-3.0mg/kg po bid (starting dose) for 48 weeks
50mg/kg po bid (starting dose) for 48 weeks
Plasma Trough Concentrations (Ctrough) for Saquinavir
Plasma trough concentration is the average steady state concentration prior to morning and evening dose. Ctrough of Saquinavir was normalized to a dose of 50 mg/kg.
Time frame: Pre-dose at Weeks 8, 12, 24.
Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Saquinavir
The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast. The area under the plasma concentration-time curve from time zero to twelve hours of saquinavir was normalized to a dose of 50 mg/kg.
Time frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an Non-nucleoside reverse transcriptase inhibitor [NNRTI] containing regimen).
Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes
Time frame: From Baseline (Day 1) till Week 48 and Follow-up (Week 52)
Change In Hematocrit From Baseline
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Change In Hemoglobin, Total Protein And Total Albumin From Baseline
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Change In White Blood Cell (WBC), Platelet, Basophil, Lymphocyte, Monocyte, Neutrophil And Eosinophil Cell Counts From Baseline
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Change In Red Blood Cell (RBC) Counts From Baseline
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Change In Creatine Kinase (CK), Serum Glutamic Oxaloacetic Transaminase (SGOT), Alkaline Phosphatase (ALP), Serum Glutamic-Pyruvic Transaminase (SGPT), Gamma-Glutamyl Transferase (GGT) Counts From Baseline
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Change In Total Bilirubin, Creatinine, Uric Acid From Baseline
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Change In Blood Urea Nitrogen (BUN), Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL Cholesterol), Triglycerides, Calcium, Potassium, Sodium, Chloride, Phosphate, Fasting Glucose From Baseline
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Change In Hematuria, Glycosuria And Proteinuria From Baseline
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Plasma Trough Concentrations (Ctrough) for Ritonavir
Plasma trough concentration is the average steady state concentration prior to morning and evening dose. Ctrough of Ritonavir was normalized to a dose of 100 mg/kg.
Time frame: Pre-dose at Weeks 8, 12, 24
Maximum Observed Concentration (Cmax) for Saquinavir and Ritonavir
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration. Cmax was normalized to a dose of 50 mg/kg for Saquinavir and100 mg/kg for Ritonavir.
Time frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen and at Week 24
Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Ritonavir
The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast. The area under the plasma concentration-time curve from time zero to twelve hours of ritonasvir was normalized to a dose of 100 mg/kg.
Time frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen).
Change From Baseline in Mean Human Immunodeficiency Virus Viral Load
Change from baseline in plasma HIV-1 RNA was derived as Change from baseline = Log10 (HIV-1 RNA at week x) - Log10 (HIV-1 RNA at baseline)
Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
Number of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <400 Copies/mL
The number of participants with HIV-1 RNA results \<400 copies/mL were reported
Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
Number of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <50 Copies/mL
The number of participants with HIV-1 RNA results \<50 copies/mL were reported.
Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
Number of Participants With >1 Log Decrease From Baseline in Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA )
The number of participants experiencing a greater than 1 log drop from baseline (day 1) (log 10 transformed) were reported
Time frame: From Week 8 till Week 48
Number of Participants With Virological Failure
Virological failure was defined as: viral load \>= 400 copies/mL on two consecutive occasions (missing visits was assumed to be above 400 copies/mL). The number of participants classified as virological failure by Age Group and viral load (≤ 10,000 copies, \>10,000 copies) were presented.
Time frame: From Week 12 till Week 48
Change From Baseline in Cluster Differentiation Antigen 4 (CD4) Lymphocyte Count
Change from Baseline in CD4+ lymphocyte count at 24 weeks and 48 weeks were presented by age group. Change from baseline in CD4+ lymphocyte count was derived as follows: Change from baseline = (CD4+ count at week 24/48) - (CD4+ count at baseline). A baseline collection was made if there was not already a value available taken within the previous 4 weeks. Baseline was on Day 1.
Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation
Change From Baseline in Cluster Differentiation Antigen 8 (CD8) Lymphocyte Count
Change from baseline in CD8+ lymphocyte count at 24 weeks and 48 weeks were presented by age group. Change from baseline in CD8+ lymphocyte count was derived as follows: Change from baseline = (CD8+ count at week 24/48) - (CD8+ count at baseline). A baseline collection was made if there was not already a value available taken within the previous 4 weeks. Baseline was on Day 1.
Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation
A total of 18 participants were recruited from 8 centers in Argentina (3 centers), Spain (1 center) and Thailand (4 centers). This study was conducted between May 20, 2008 and March 11, 2010.
| Milestone | Group A | Group B |
|---|---|---|
| Started | 5 | 13 |
| Completed | 4 | 13 |
| Not completed | 1 | 0 |
| Withdrew: Failed to return | 1 | 0 |
Plasma trough concentration is the average steady state concentration prior to morning and evening dose. Ctrough of Saquinavir was normalized to a dose of 50 mg/kg.
| ng/mL | Group A | Group B |
|---|---|---|
| Plasma Trough Concentrations (Ctrough) for Saquinavir | 645 ± 536 | 1860 ± 1060 |
The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast. The area under the plasma concentration-time curve from time zero to twelve hours of saquinavir was normalized to a dose of 50 mg/kg.
| h*ug/mL | Group A | Group B |
|---|---|---|
| Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Saquinavir | 18.7 ± 20.0 | 38 ± 18.1 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes
| participants | Group A | Group B | Total |
|---|---|---|---|
| Any serious adverse events | 1 | 2 | 3 |
| Any non-serious adverse events | 5 | 9 | 14 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| fraction | Group A | Group B | Total |
|---|---|---|---|
| Change from Baseline at Week 24 (n= 4, 13, 17) | 0.01 ± 0.011 | -0 ± 0.03 | -0 ± 0.027 |
| Change from Baseline at Week 48 (n= 4, 13, 17) | 0.03 ± 0.037 | -0.01 ± 0.044 | 0 ± 0.044 |
Plasma trough concentration is the average steady state concentration prior to morning and evening dose. Ctrough of Ritonavir was normalized to a dose of 100 mg/kg.
| ng/mL | Group A | Group B |
|---|---|---|
| Plasma Trough Concentrations (Ctrough) for Ritonavir | 577 ± 366 | 995 ± 548 |
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration. Cmax was normalized to a dose of 50 mg/kg for Saquinavir and100 mg/kg for Ritonavir.
| ng/mL | Group A | Group B |
|---|---|---|
| Saquinavir | 2910 ± 3110 | 5570 ± 2780 |
| Ritonavir | 2050 ± 1270 | 3370 ± 2020 |
The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast. The area under the plasma concentration-time curve from time zero to twelve hours of ritonasvir was normalized to a dose of 100 mg/kg.
| h*ug/mL | Group A | Group B |
|---|---|---|
| Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Ritonavir | 13.6 ± 8.18 | 21.8 ± 11.6 |
Change from baseline in plasma HIV-1 RNA was derived as Change from baseline = Log10 (HIV-1 RNA at week x) - Log10 (HIV-1 RNA at baseline)
| log10 copies/mL | Group A | Group B | Total |
|---|---|---|---|
| Change from Baseline at Week 24 (n= 3, 13, 16) | -0.75 ± 1.48 | -1.81 ± 1.57 | -1.61 ± 1.57 |
| Change from Baseline at Week 48 (n= 3, 13, 16) | -1.27 ± 1.01 | -1.39 ± 1.53 | -1.36 ± 1.42 |
The number of participants with HIV-1 RNA results \<400 copies/mL were reported
| participants | Group A | Group B | Total |
|---|---|---|---|
| Baseline (n= 5, 13, 18) | 1 | 5 | 6 |
| Week 24 (n= 3, 13, 16) | 2 | 13 | 15 |
| Week 48 (n= 3, 13, 16) | 2 | 11 | 13 |
The number of participants with HIV-1 RNA results \<50 copies/mL were reported.
| participants | Group A | Group B | Total |
|---|---|---|---|
| Baseline (n= 5, 13, 18) | 0 | 4 | 4 |
| Week 24 (n= 3, 13, 16) | 2 | 11 | 13 |
| Week 48 (n= 3, 13, 16) | 2 | 9 | 11 |
The number of participants experiencing a greater than 1 log drop from baseline (day 1) (log 10 transformed) were reported
| participants | Group A | Group B | Total |
|---|---|---|---|
| Week 8 (n= 4, 12, 16) | 1 | 7 | 8 |
| Week 24 (n= 3, 13, 16) | 1 | 8 | 9 |
| Week 48 (n= 3, 13, 16) | 1 | 7 | 8 |
Virological failure was defined as: viral load \>= 400 copies/mL on two consecutive occasions (missing visits was assumed to be above 400 copies/mL). The number of participants classified as virological failure by Age Group and viral load (≤ 10,000 copies, \>10,000 copies) were presented.
| participants | Group A | Group B | Total |
|---|---|---|---|
| VF at Week 12 (n= 5, 13, 18) | 2 | 1 | 3 |
| VF at Week 24 (n= 5, 13, 18) | 2 | 0 | 2 |
| VF at Week 48 (n= 5, 13, 18) | 3 | 1 | 4 |
| HIV-RNA <= 10,000 copies/mL at Wk 12 (n= 3, 6, 9) | 1 | 0 | 1 |
| HIV-RNA <= 10,000 copies/mL at Wk 24 (n= 3, 6, 9) | 1 | 0 | 1 |
| HIV-RNA <= 10,000 copies/mL at Wk 48 (n= 3, 6, 9) | 2 | 0 | 2 |
| HIV-RNA >10,000 copies/mL at Week 12 (n= 2, 7, 9) | 1 | 1 | 2 |
| HIV-RNA >10,000 copies/mL at Week 24 (n= 2, 7, 9) | 1 | 0 | 1 |
| HIV-RNA >10,000 copies/mL at Week 48 (n= 2, 7, 9) | 1 | 1 | 2 |
Change from Baseline in CD4+ lymphocyte count at 24 weeks and 48 weeks were presented by age group. Change from baseline in CD4+ lymphocyte count was derived as follows: Change from baseline = (CD4+ count at week 24/48) - (CD4+ count at baseline). A baseline collection was made if there was not already a value available taken within the previous 4 weeks. Baseline was on Day 1.
| count/uL | Group A | Group B | Total |
|---|---|---|---|
| Change from Baseline at Week 24 (n= 3, 12, 15) | 94.90 ± 643.28 | -34.53 ± 821.31 | -8.65 ± 769.41 |
| Change from Baseline at Week 48 (n= 3, 12, 15) | -50.07 ± 1013.23 | 126.11 ± 528.49 | 90.87 ± 609.46 |
Change from baseline in CD8+ lymphocyte count at 24 weeks and 48 weeks were presented by age group. Change from baseline in CD8+ lymphocyte count was derived as follows: Change from baseline = (CD8+ count at week 24/48) - (CD8+ count at baseline). A baseline collection was made if there was not already a value available taken within the previous 4 weeks. Baseline was on Day 1.
| count/uL | Group A | Group B | Total |
|---|---|---|---|
| Change from Baseline at Week 24 (n= 3, 12, 15) | -200.49 ± 161.05 | -3.50 ± 790.86 | -42.90 ± 708.37 |
| Change from Baseline at Week 48 (n= 3, 12, 15) | -92.07 ± 455.23 | 40.52 ± 641.27 | 14.00 ± 596.43 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| g/L | Group A | Group B | Total |
|---|---|---|---|
| Hemoglobin, Change from BL at Wk 24 (n= 4, 13, 17) | -0 ± 3.3 | 1 ± 12.1 | 1 ± 10.6 |
| Hemoglobin, Change from BL at Wk 48 (n= 4, 13, 17) | 6 ± 11.8 | 0 ± 14.4 | 2 ± 13.7 |
| Total Protein, Change from BL at Wk 24 (n=4,13,17) | -4 ± 6.0 | 2 ± 12.6 | 0 ± 11.5 |
| Total Protein, Change from BL at Wk 48 (n=4,13,17) | -5 ± 5.7 | -0 ± 14.3 | -1 ± 12.8 |
| Total Albumin, Change from BL at Wk 24 (n=4,13,17) | 0.5 ± 5.41 | 5 ± 7.68 | 4 ± 7.32 |
| Total Albumin, Change from BL at Wk 48 (n=4,13,17) | 1.3 ± 2.29 | 4 ± 8.7 | 3.4 ± 7.7 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| 10*9/L | Group A | Group B | Total |
|---|---|---|---|
| WBC, Change from BL at Wk 24 (n= 4,13,17) | -3 ± 2.31 | -1 ± 4.35 | -1.5 ± 4.0 |
| WBC, Change from BL at Wk 48 (n= 4,13,17) | -2.1 ± 1.72 | -0.9 ± 4.38 | -1.2 ± 3.9 |
| Platelet, Change from BL at Wk 24 (n= 4,13,17) | -119 ± 93.4 | 24 ± 148.9 | -9 ± 148.9 |
| Platelet, Change from BL at Wk 48 (n= 4,13,17) | -50 ± 130.4 | -2 ± 118.9 | -13 ± 119.3 |
| Basophil, Change from BL at Wk 24 (n=4 ,13,17) | -0.02 ± 0.028 | 0 ± 0.031 | -0.01 ± 0.031 |
| Basophil, Change from BL at Wk 48 (n=4 ,13,17) | -0 ± 0.03 | -0.01 ± 0.029 | -0.01 ± 0.028 |
| Lymphocyte, Change from BL at Wk 24 (n=2, 2, 4) | -0.9 ± 0.3 | -1.1 ± 1.20 | -1 ± 0.72 |
| Lymphocyte, Change from BL at Wk 48 (n= 2, 2, 4) | -1.5 ± 0.29 | -0.7 ± 1.05 | -1.1 ± 0.76 |
| Monocyte, Change from BL at Wk 24 (n= ,13,17) | -0.41 ± 0.295 | -0.01 ± 0.361 | -0.11 ± 0.379 |
| Monocyte, Change from BL at Wk 48 (n= ,13,17) | -0.21 ± 0.179 | -0.05 ± 0.384 | -0.09 ± 0.348 |
| Neutrophil, Change from BL at Wk 24 (n=2, 2, 4) | -1.4 ± 0.33 | -2.8 ± 1.87 | -2.1 ± 1.36 |
| Neutrophil, Change from BL at Wk 48 (n= 2, 2, 4) | -1.7 ± 1.15 | -1.6 ± 2.55 | -1.6 ± 1.62 |
| Eosinophil, Change from BL at Wk 24 (n=2, 2, 4) | -0 ± 0.2 | -0 ± 0.1 | -0 ± 0.1 |
| Eosinophil, Change from BL at Wk 48 (n= 2, 2, 4) | -0 ± 0.2 | 0 ± 1.1 | 0 ± 0.7 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| 10*12/L | Group A | Group B | Total |
|---|---|---|---|
| RBC,Change from Baseline at Week 24 (n= 4, 13, 17) | -0.18 ± 0.227 | -0.07 ± 0.673 | -0.1 ± 0.593 |
| RBC,Change from Baseline at Week 48 (n= 4, 13, 17) | 0.02 ± 0.125 | -0.16 ± 0.74 | -0.12 ± 0.648 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| U/L | Group A | Group B | Total |
|---|---|---|---|
| CK, Change from Baseline at Week 24 (n= 3, 3, 16) | 112 ± 112.0 | -12 ± 115.9 | 11 ± 122.2 |
| CK, Change from Baseline at Week 48 (n= 3, 3, 16) | 257 ± 244.8 | -7 ± 84 | 43 ± 158 |
| SGOT, Change from Baseline at Week 24 (n= 4,13,17) | -0 ± 1.5 | -0 ± 8.2 | -0 ± 7.1 |
| SGOT, Change from Baseline at Week 48 (n= 4,13,17) | -1 ± 7.8 | -0 ± 6.9 | -0 ± 6.8 |
| ALP, Change from Baseline at Week 24 (n=4, 12, 16) | 10 ± 29.8 | 26 ± 23.2 | 22 ± 24.9 |
| ALP, Change from Baseline at Week 48 (n=4, 12, 16) | 47 ± 87.6 | 36 ± 26.5 | 39 ± 45.6 |
| SGPT, Change from Baseline at Week 24 (n=4,13,17) | -9 ± 15.3 | -2 ± 13.6 | -4 ± 13.8 |
| SGPT, Change from Baseline at Week 48 (n=4,13,17) | -2 ± 13.4 | -3 ± 12.1 | -3 ± 12 |
| GGT, Change from Baseline at Week 24 (n=4, 13, 17) | 5 ± 4.7 | -7 ± 18.7 | -4 ± 17.1 |
| GGT, Change from Baseline at Week 48 (n=4, 13, 17) | 5 ± 2.1 | -5 ± 18.5 | -2 ± 16.7 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| umol/L | Group A | Group B | Total |
|---|---|---|---|
| Total Bilirubin-Change from BL at Wk 24(n=4,12,16) | 2 ± 2.8 | 2 ± 5.5 | 2 ± 4.9 |
| Total Bilirubin-Change from BL at Wk 48(n=4,12,16) | 1 ± 1.1 | 2 ± 6.9 | 1 ± 5.9 |
| Cretainine- Change from BL at Wk 24 (n=4, 13,17) | -2 ± 6.7 | 3 ± 10 | 2 ± 9.5 |
| Cretainine- Change from BL at Wk 48 (n=4, 13,17) | 3 ± 10.7 | 5 ± 9.2 | 5 ± 9.3 |
| Uric acid- Change from BL at Wk 24 (n=4, 13,17) | -27 ± 54.3 | 68 ± 55.1 | 46 ± 67.6 |
| Uric acid- Change from BL at Wk 48 (n=3,13,16) | -42 ± 108.4 | 61 ± 63.5 | 41 ± 80.6 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| mmol/L | Group A | Group B | Total |
|---|---|---|---|
| BUN,Change from Baseline at Week 24 (n= 3, 13, 16) | -1.5 ± 2.78 | 1 ± 2.2 | 0.5 ± 2.43 |
| BUN,Change from Baseline at Week 48 (n= 3, 13, 16) | 0.4 ± 0.66 | 1.1 ± 2.0 | 0.9 ± 1.82 |
| LDL,Change from Baseline at Week 24 (n= 3, 13, 16) | 0.21 ± 0.237 | 0.21 ± 1.389 | 0.21 ± 1.245 |
| LDL,Change from Baseline at Week 48 (n= 3, 13, 16) | 0.23 ± 0.596 | -0.11 ± 1.038 | -0.04 ± 0.963 |
| HDL,Change from Baseline at Week 24 (n= 3, 13, 16) | 0.21 ± 0.202 | 0.13 ± 0.369 | 0.15 ± 0.34 |
| HDL,Change from Baseline at Week 48 (n= 3, 13, 16) | 0.41 ± 0.233 | 0.17 ± 0.387 | 0.21 ± 0.37 |
| Triglyceride,Change from BL at Wk 24 (n=4,13, 17) | -0.28 ± 0.597 | -0.19 ± 1.376 | -0.21 ± 1.22 |
| Triglyceride,Change from BL at Wk 48 (n=4,13, 17) | -0.19 ± 0.496 | -0.15 ± 1.558 | -0.16 ± 1.366 |
| Calcium,Change from BL at Wk 24 (n=2, 12, 14) | -0.15 ± 0.04 | 0.15 ± 0.17 | 0.11 ± 0.19 |
| Calcium,Change from BL at Wk 48 (n=2, 12, 14) | -0.16 ± 0.09 | 0.09 ± 0.17 | 0.06 ± 0.18 |
| Potassium,Change from BL at Wk 24 (n=4,13, 17) | -0.1 ± 0.16 | -0.3 ± 0.63 | -0.2 ± 0.56 |
| Potassium,Change from BL at Wk 48 (n=4,13, 17) | 0.2 ± 0.59 | -0.2 ± 0.54 | -0.1 ± 0.57 |
| Sodium,Change from BL at Wk 24 (n=4,13, 17) | 2 ± 1.3 | -1 ± 2.3 | -0 ± 2.3 |
| Sodium,Change from BL at Wk 48 (n=4,13, 17) | 1 ± 2.2 | -1 ± 3.8 | -0 ± 3.5 |
| Chloride,Change from BL at Wk 24 (n=4,13, 17) | -1 ± 2.8 | -2 ± 4.2 | -2 ± 3.9 |
| Chloride,Change from BL at Wk 48 (n=4,13, 17) | 1 ± 1.3 | -2 ± 3.6 | -1 ± 3.3 |
| Phosphate,Change from BL at Wk 24 (n=2, 12, 14) | -0.02 ± 0.114 | 0.17 ± 0.188 | 0.14 ± 0.188 |
| Phosphate,Change from BL at Wk 48 (n=2, 13, 15) | -0.26 ± 0.0 | 0.12 ± 0.212 | 0.07 ± 0.237 |
| Fasting Glucose,Change from BL at Wk 24(n=4,13,17) | -0.26 ± 0.963 | 0.02 ± 1.253 | -0.05 ± 1.169 |
| Fasting Glucose,Change from BL at Wk 48(n=4,13,17) | -0.07 ± 0.857 | 0.14 ± 1.537 | 0.09 ± 1.385 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| [0 to 4+] | Group A | Group B | Total |
|---|---|---|---|
| Hematuria-Change from BL at Wk 24 (n= 1, 2, 3) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Hematuria-Change from BL at Wk 48 (n= 1, 2, 3) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Glycosuria-Change from BL at Wk 24 (n= 1, 2, 3) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Glycosuria-Change from BL at Wk 48 (n= 1, 2, 3) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Proteinuria-Change from BL at Wk 24 (n= 1, 2, 3) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Proteinuria-Change from BL at Wk 48 (n= 1, 2, 3) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
Collected over Up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A | — | 1/5 (20%) | 5/5 (100%) |
| Group B | — | 2/13 (15.4%) | 9/13 (69.2%) |
| Total | — | 3/18 (16.7%) | 14/18 (77.8%) |
| Event | Group A | Group B | Total |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/5 | 1/13 | 2/18 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 0/5 | 1/13 | 1/18 |
| Event | Group A | Group B | Total |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/5 | 0/13 | 2/18 |
| DiarrhoeaGastrointestinal disorders | 0/5 | 3/13 | 3/18 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/5 | 1/13 | 2/18 |
| GiardiasisInfections and infestations | 1/5 | 0/13 | 1/18 |
| NasopharyngitisInfections and infestations | 1/5 | 0/13 | 1/18 |
| ToxocariasisInfections and infestations | 1/5 | 0/13 | 1/18 |
| VomitingGastrointestinal disorders | 1/5 | 2/13 | 3/18 |
| Dental CariesGastrointestinal disorders | 1/5 | 2/13 | 3/18 |
| Abdominal PainGastrointestinal disorders | 1/5 | 0/13 | 1/18 |
| Gait DisturbanceGeneral disorders | 1/5 | 0/13 | 1/18 |
The Safety Analysis Population (SAP) comprised all participants who received at least one dose of study medication. The SAP was used for all efficacy and safety analyses
| Age, Continuous(years) | Group A | Group B | Total |
|---|---|---|---|
| Mean | 0.8 ± 0.45 | 4.0 ± 1.08 | 3.1 ± 1.75 |
| Sex: Female, Male(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Female | 3 | 8 | 11 |
| Male | 2 | 5 | 7 |
Plan to share: Yes
No publications or documents are linked to this record.
The record gives a start of Jun 2008, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ritonavir